Mortality risk in transgender people is twice as high as in cisgender people, data showBMJ 2021; 374 doi: https://doi.org/10.1136/bmj.n2169 (Published 02 September 2021) Cite this as: BMJ 2021;374:n2169
- Jacqui Wise
The mortality risk in transgender people using hormone treatment is twice as high as in cisgender people and has not decreased in the past five decades, a Dutch retrospective analysis has suggested.1
However, the researchers concluded that the increased mortality risk in transgender people did not seem to be a specific effect of gender affirming hormone treatment.
Transgender people often seek medical treatment to bring about physical changes that more closely match their gender identify, and this can include hormone treatment and surgery. For transgender women, gender affirming hormone treatment consists of oestrogen in combination with a testosterone lowering medication. For transgender men gender affirming hormone treatment consists of testosterone.
The study, published in the Lancet Diabetes & Endocrinology,1 included 2927 transgender women and 1641 transgender men who visited the gender identity clinic of Amsterdam University Medical Centre …